Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at
Wall S
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Verrica Pharmaceuticals (NASDAQ:VRCA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.